The effectiveness of ferritin as a contrast agent for cell tracking MRI in mouse cancer models

Chan Wha Lee, Sun Il Choi, Sang Jin Lee, Young Taek Oh, Gunwoo Park, Na Yeon Park, Kyoung Ah Yoon, Sunshin Kim, Daehong Kim, Yun Hee Kim, Jinsuck Suh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: We aimed to investigate the effectiveness of ferritin as a contrast agent and a potential reporter gene for tracking tumor cells or macrophages in mouse cancer models. Materials and Methods: Adenoviral human ferritin heavy chain (Ad-hFTH) was administrated to orthotopic glioma models and subcutaneous colon cancer mouse models using U87MG and HCT116 cells, respectively. Brain MR images were acquired before and daily for up to 6 days after the intracranial injection of Ad-hFTH. In the HCT116 tumor model, MR examinations were performed before and at 6, 24, and 48 h after intratumoral injection of Ad-hFTH, as well as before and every two days after intravenous injection of ferritin-labeled macrophages. The contrast effect of ferritin in vitro was measured by MR imaging of cell pellets. MRI examinations using a 7T MR scanner comprised a T1-weighted (T1w) spin-echo sequence, T2-weighted (T2w) relaxation enhancement sequence, and T2*-weighted (T2*w) fast low angle shot sequence. Results: Cell pellet imaging of Ad-hFTH in vitro showed a strong negatively enhanced contrast in T2w and T2*w images, presenting with darker signal intensity in high concentrations of Fe. T2w images of glioma and subcutaneous HCT116 tumor models showed a dark signal intensity around or within the Ad-hFTH tumor, which was distinct with time and apparent in T2*w images. After injection of ferritin-labeled macrophages, negative contrast enhancement was identified within the tumor. Conclusion: Ferritin could be a good candidate as an endogenous MR contrast agent and a potential reporter gene that is capable of maintaining cell labeling stability and cellular safety.

Original languageEnglish
Pages (from-to)51-58
Number of pages8
JournalYonsei medical journal
Volume58
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Cell Tracking
Apoferritins
Ferritins
Contrast Media
Neoplasms
Macrophages
Reporter Genes
Glioma
Injections
HCT116 Cells
Intravenous Injections
Colonic Neoplasms
Safety
Brain

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lee, Chan Wha ; Choi, Sun Il ; Lee, Sang Jin ; Oh, Young Taek ; Park, Gunwoo ; Park, Na Yeon ; Yoon, Kyoung Ah ; Kim, Sunshin ; Kim, Daehong ; Kim, Yun Hee ; Suh, Jinsuck. / The effectiveness of ferritin as a contrast agent for cell tracking MRI in mouse cancer models. In: Yonsei medical journal. 2017 ; Vol. 58, No. 1. pp. 51-58.
@article{fcad3c4673a14a43bfbfc693dd8da20e,
title = "The effectiveness of ferritin as a contrast agent for cell tracking MRI in mouse cancer models",
abstract = "Purpose: We aimed to investigate the effectiveness of ferritin as a contrast agent and a potential reporter gene for tracking tumor cells or macrophages in mouse cancer models. Materials and Methods: Adenoviral human ferritin heavy chain (Ad-hFTH) was administrated to orthotopic glioma models and subcutaneous colon cancer mouse models using U87MG and HCT116 cells, respectively. Brain MR images were acquired before and daily for up to 6 days after the intracranial injection of Ad-hFTH. In the HCT116 tumor model, MR examinations were performed before and at 6, 24, and 48 h after intratumoral injection of Ad-hFTH, as well as before and every two days after intravenous injection of ferritin-labeled macrophages. The contrast effect of ferritin in vitro was measured by MR imaging of cell pellets. MRI examinations using a 7T MR scanner comprised a T1-weighted (T1w) spin-echo sequence, T2-weighted (T2w) relaxation enhancement sequence, and T2*-weighted (T2*w) fast low angle shot sequence. Results: Cell pellet imaging of Ad-hFTH in vitro showed a strong negatively enhanced contrast in T2w and T2*w images, presenting with darker signal intensity in high concentrations of Fe. T2w images of glioma and subcutaneous HCT116 tumor models showed a dark signal intensity around or within the Ad-hFTH tumor, which was distinct with time and apparent in T2*w images. After injection of ferritin-labeled macrophages, negative contrast enhancement was identified within the tumor. Conclusion: Ferritin could be a good candidate as an endogenous MR contrast agent and a potential reporter gene that is capable of maintaining cell labeling stability and cellular safety.",
author = "Lee, {Chan Wha} and Choi, {Sun Il} and Lee, {Sang Jin} and Oh, {Young Taek} and Gunwoo Park and Park, {Na Yeon} and Yoon, {Kyoung Ah} and Sunshin Kim and Daehong Kim and Kim, {Yun Hee} and Jinsuck Suh",
year = "2017",
month = "1",
day = "1",
doi = "10.3349/ymj.2017.58.1.51",
language = "English",
volume = "58",
pages = "51--58",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "1",

}

Lee, CW, Choi, SI, Lee, SJ, Oh, YT, Park, G, Park, NY, Yoon, KA, Kim, S, Kim, D, Kim, YH & Suh, J 2017, 'The effectiveness of ferritin as a contrast agent for cell tracking MRI in mouse cancer models', Yonsei medical journal, vol. 58, no. 1, pp. 51-58. https://doi.org/10.3349/ymj.2017.58.1.51

The effectiveness of ferritin as a contrast agent for cell tracking MRI in mouse cancer models. / Lee, Chan Wha; Choi, Sun Il; Lee, Sang Jin; Oh, Young Taek; Park, Gunwoo; Park, Na Yeon; Yoon, Kyoung Ah; Kim, Sunshin; Kim, Daehong; Kim, Yun Hee; Suh, Jinsuck.

In: Yonsei medical journal, Vol. 58, No. 1, 01.01.2017, p. 51-58.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effectiveness of ferritin as a contrast agent for cell tracking MRI in mouse cancer models

AU - Lee, Chan Wha

AU - Choi, Sun Il

AU - Lee, Sang Jin

AU - Oh, Young Taek

AU - Park, Gunwoo

AU - Park, Na Yeon

AU - Yoon, Kyoung Ah

AU - Kim, Sunshin

AU - Kim, Daehong

AU - Kim, Yun Hee

AU - Suh, Jinsuck

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: We aimed to investigate the effectiveness of ferritin as a contrast agent and a potential reporter gene for tracking tumor cells or macrophages in mouse cancer models. Materials and Methods: Adenoviral human ferritin heavy chain (Ad-hFTH) was administrated to orthotopic glioma models and subcutaneous colon cancer mouse models using U87MG and HCT116 cells, respectively. Brain MR images were acquired before and daily for up to 6 days after the intracranial injection of Ad-hFTH. In the HCT116 tumor model, MR examinations were performed before and at 6, 24, and 48 h after intratumoral injection of Ad-hFTH, as well as before and every two days after intravenous injection of ferritin-labeled macrophages. The contrast effect of ferritin in vitro was measured by MR imaging of cell pellets. MRI examinations using a 7T MR scanner comprised a T1-weighted (T1w) spin-echo sequence, T2-weighted (T2w) relaxation enhancement sequence, and T2*-weighted (T2*w) fast low angle shot sequence. Results: Cell pellet imaging of Ad-hFTH in vitro showed a strong negatively enhanced contrast in T2w and T2*w images, presenting with darker signal intensity in high concentrations of Fe. T2w images of glioma and subcutaneous HCT116 tumor models showed a dark signal intensity around or within the Ad-hFTH tumor, which was distinct with time and apparent in T2*w images. After injection of ferritin-labeled macrophages, negative contrast enhancement was identified within the tumor. Conclusion: Ferritin could be a good candidate as an endogenous MR contrast agent and a potential reporter gene that is capable of maintaining cell labeling stability and cellular safety.

AB - Purpose: We aimed to investigate the effectiveness of ferritin as a contrast agent and a potential reporter gene for tracking tumor cells or macrophages in mouse cancer models. Materials and Methods: Adenoviral human ferritin heavy chain (Ad-hFTH) was administrated to orthotopic glioma models and subcutaneous colon cancer mouse models using U87MG and HCT116 cells, respectively. Brain MR images were acquired before and daily for up to 6 days after the intracranial injection of Ad-hFTH. In the HCT116 tumor model, MR examinations were performed before and at 6, 24, and 48 h after intratumoral injection of Ad-hFTH, as well as before and every two days after intravenous injection of ferritin-labeled macrophages. The contrast effect of ferritin in vitro was measured by MR imaging of cell pellets. MRI examinations using a 7T MR scanner comprised a T1-weighted (T1w) spin-echo sequence, T2-weighted (T2w) relaxation enhancement sequence, and T2*-weighted (T2*w) fast low angle shot sequence. Results: Cell pellet imaging of Ad-hFTH in vitro showed a strong negatively enhanced contrast in T2w and T2*w images, presenting with darker signal intensity in high concentrations of Fe. T2w images of glioma and subcutaneous HCT116 tumor models showed a dark signal intensity around or within the Ad-hFTH tumor, which was distinct with time and apparent in T2*w images. After injection of ferritin-labeled macrophages, negative contrast enhancement was identified within the tumor. Conclusion: Ferritin could be a good candidate as an endogenous MR contrast agent and a potential reporter gene that is capable of maintaining cell labeling stability and cellular safety.

UR - http://www.scopus.com/inward/record.url?scp=84995739664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995739664&partnerID=8YFLogxK

U2 - 10.3349/ymj.2017.58.1.51

DO - 10.3349/ymj.2017.58.1.51

M3 - Article

VL - 58

SP - 51

EP - 58

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 1

ER -